These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 8133047)

  • 21. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
    Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
    Zollner TM; Zhu HG; Anderer FA
    Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
    J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin.
    Street NE; Fulton RJ; Sanders VM; Vitetta ES
    J Immunol; 1987 Sep; 139(5):1734-8. PubMed ID: 2957434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
    J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
    Gallinger S; Hoskin DW; Mullen JB; Wong AH; Roder JC
    Cancer Res; 1990 Apr; 50(8):2476-80. PubMed ID: 2138507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
    Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
    Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
    Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T
    Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
    French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
    Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
    Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
    Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different expression of CD3 and CD22 in leukemic cells according to whether tested in suspension or fixed on slides.
    Rani S; De Oliveira MS; Catovsky D
    Hematol Pathol; 1988; 2(2):73-8. PubMed ID: 2974027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
    Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.